Key facts
- · Type: Amendment first sale 2025-09-24 · Amount sold: $4.01M · Total offering: $5M · SEC filing
- · Type: New offering first sale 2025-09-24 · Amount sold: $160K · Total offering: $5M · SEC filing
- · Type: New offering first sale 2024-08-23 · Amount sold: $720K · Total offering: $3.50M · SEC filing
- · Type: New offering first sale 2023-04-14 · Amount sold: $25K · Total offering: $3M · SEC filing
NORMANDY PARK, WASHINGTON
Biotechnology
4
$905K
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-10-22 | Amendment first sale 2025-09-24 | $4.01M | $5M | details · SEC filing |
| 2025-10-06 | New offering first sale 2025-09-24 | $160K | $5M | SEC filing |
| 2024-11-01 | New offering first sale 2024-08-23 | $720K | $3.50M | SEC filing |
| 2023-04-25 | New offering first sale 2023-04-14 | $25K | $3M | SEC filing |
Keep reading
More on Inmedix, Inc. and the records around it.
Inmedix, Inc. elsewhere on the record
- Form D filing Oct 2026
Watch Inmedix, Inc.
Get an email when Inmedix, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Inmedix, Inc.?
Who to contact
- Andrew Holman, M.D. — Executive Officer, Director
- Steven Daly, M.S., M.B.A. — Director
- Bernie Tobin — Director
- Leroy Hood, M.D., Ph.D. — Director
- Kevin Tracey, M.D. — Director
- Ryan Sullivan, Ph.D. — Director
- Round: Form D/A (amended) filed 2026-10-22
- Amount sold: $4.01M
- Industry: Biotechnology
- Based: NORMANDY PARK, WASHINGTON
People listed
- Andrew Holman, M.D. — Executive Officer, Director
- Steven Daly, M.S., M.B.A. — Director
- Bernie Tobin — Director
- Leroy Hood, M.D., Ph.D. — Director
- Kevin Tracey, M.D. — Director
- Ryan Sullivan, Ph.D. — Director
- Filing: Form D/A (amended) filed 2026-10-22
- Amount sold: $4.01M
- Industry group: Biotechnology
- Based: NORMANDY PARK, WASHINGTON
- Entity type: Corporation
We'll show it in your MentionFox inbox when Inmedix, Inc. raises, hires or launches. No email unless you switch it on.
Watch Inmedix, Inc. →Want the whole picture on Inmedix, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Inmedix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inmedix, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Inmedix, Inc.'s own filings with the SEC. The people those filings name are on the team page.